In recent years, treatment of animal models of AD or MCI with thiazolidinediones, a PPAR-γ agonists, demonstrated an improvement in memory performance and a reduction in amyloid burden and inflammation [12,13,14,15]. This evidence concerns the gene PPARG and Alzheimer disease.